Patient characteristics
| . | Letermovir group . | Comparator group (no letermovir) . |
|---|---|---|
| No. of patients | 110 | 234 |
| Median follow-up (d) | 131 (3-311) | 688 (21-4158) |
| Median age (y) | 59 (15-73) | 49 (19-68) |
| Sex | ||
| Female | 46 | 96 |
| Male | 64 | 138 |
| CMV status | ||
| Pos/Pos | 81 | 193 |
| Pos/Neg | 29 | 41 |
| Diagnosis | ||
| ALL | 9 | 24 |
| AML/MDS | 66 | 90 |
| Lymphoma | 15 | 108 |
| CLL/PLL | 2 | 7 |
| Aplastic anemia | 8 | 0 |
| MPD/myelofibrosis | 0 | 3 |
| CML/CMML | 8 | 1 |
| Immunodeficiency syndrome | 2 | 1 |
| Donor | ||
| Sibling | 25 | 104 |
| MUD | 63 | 81 |
| MMUD | 22 | 49 |
| Conditioning regimen | ||
| Myeloablative | 10 | 42 |
| Reduced intensity | 100 | 192 |
| Maximum GVHD grade | ||
| 0 to 1 | 79 | 170 |
| 2 | 20 | 44 |
| 3 to 4 | 7 | 19 |
| Unknown | 4 | 1 |
| . | Letermovir group . | Comparator group (no letermovir) . |
|---|---|---|
| No. of patients | 110 | 234 |
| Median follow-up (d) | 131 (3-311) | 688 (21-4158) |
| Median age (y) | 59 (15-73) | 49 (19-68) |
| Sex | ||
| Female | 46 | 96 |
| Male | 64 | 138 |
| CMV status | ||
| Pos/Pos | 81 | 193 |
| Pos/Neg | 29 | 41 |
| Diagnosis | ||
| ALL | 9 | 24 |
| AML/MDS | 66 | 90 |
| Lymphoma | 15 | 108 |
| CLL/PLL | 2 | 7 |
| Aplastic anemia | 8 | 0 |
| MPD/myelofibrosis | 0 | 3 |
| CML/CMML | 8 | 1 |
| Immunodeficiency syndrome | 2 | 1 |
| Donor | ||
| Sibling | 25 | 104 |
| MUD | 63 | 81 |
| MMUD | 22 | 49 |
| Conditioning regimen | ||
| Myeloablative | 10 | 42 |
| Reduced intensity | 100 | 192 |
| Maximum GVHD grade | ||
| 0 to 1 | 79 | 170 |
| 2 | 20 | 44 |
| 3 to 4 | 7 | 19 |
| Unknown | 4 | 1 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; Neg, Negative; PLL, prolymphocytic leukemia; Pos, positive.